Clinical Reasoning Series in Pharmacotherapy — Part One

The Clinical Reasoning Series aims to deliver programs that will meaningfully contribute to advancing pharmacy specialists’ knowledge, skills, and clinical judgment. Topic selection for the program reflects content that is timely and of relevance and value to the practice of Board Pharmacotherapy Specialists (BCPS).

Participants will have the opportunity to attend four educational activities, broken into a two-part morning and a one-part afternoon session. Part One will offer 3.0 contact hours of continuing pharmacy education credit toward BCPS recertification credit upon completing the required posttests by the submission deadline and achieving a predetermined passing score. The posttests will be available on November 12, 2025. The deadline to submit posttests and earn recertification credit for the session will be November 12, 2026. If you have not already purchased posttest access and wish to add it to your registration, email [email protected] or visit the registration desk on or before October 21, 2025.

Moderator: Alyssa Robertson, Pharm.D., BCEMP, BCPS Clinical Pharmacist Specialist - Emergency Medicine WellSpan York Hospital York, PA   View Biography

Target on Oncology Pharmacotherapy: Updates, Safety, and Management of Immune Checkpoint Inhibitor and Immune Effector Cell Therapies 9:00 a.m. to 10:30 a.m. Available for 1.50 hours of CPE credit Activity Number: 0217-0000-25-108-L01-P Activity Type: An Application-Based Activity Target on Oncology Pharmacotherapy: Updates, Safety, and Management of Immune Checkpoint Inhibitor and Immune Effector Cell Therapies will focus on how the board-certified pharmacotherapy pharmacist can recognize and manage medication-related therapies and concerns in this specialized patient population. The presentation will provide a review of immune checkpoint inhibitor and immune effector cell therapy, therapeutic patient monitoring, therapy-related adverse events, and how to manage select therapy-related events. Board certified pharmacotherapy specialists who manage or encounter patients receiving oncologic medication treatment, and pharmacists who engage in medication monitoring and safety will have much to gain by attending this session. This activity offers 1.50 contact hours of CPE and/or BCPS recertification credit. Learning Objectives 1. Compare mechanism and indications between immune checkpoint inhibitor and immune effector cell therapies. 2. Recognize presentation of immune checkpoint inhibitor-related toxicity in commonly involved organ systems. 3. Design a therapeutic monitoring plan for immune checkpoint inhibitor therapy. 4. Differentiate the presentation of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). 5. Formulate a management strategy for toxicity related to immune effector cell therapy. Speaker: Lauren Ice, Pharm.D., BCOP, BCPS Pharmacy Supervisor, Cancer Health & Transplant Corewell Health Grand Rapids, Michigan   View Biography

Break in Programming 10:30 a.m. to 10:45 a.m.

Revolutionizing Pulmonary Care: Integrating Medication Management into Practice 10:45 a.m. to 12:15 a.m. Available for 1.50 hours of CPE credit Activity Number: 0217-0000-25-109-L01-P Activity Type: An Application-Based Activity Revolutionizing Pulmonary Care: Integrating Medication Management into Practice will provide a review of recently approved medications for asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea with comorbid obesity. The session will explore current approaches to identifying and managing overlapping features of asthma and COPD, termed asthma-COPD overlap, and management of severe disease with a focus on biologic agents. The presentation will also emphasize the critical role of the pharmacist in patient-centered education and implementing updated immunization recommendations relevant to pulmonary care. Participants will engage with current literature to support diagnosis, identify disease-specific factors influencing pharmacotherapy, and apply appropriate monitoring strategies to optimize treatment outcomes. This activity offers 1.50 contact hours of CPE and/or BCPS recertification credit. Learning Objectives 1. Differentiate the clinical features and management approaches of asthma, chronic obstructive pulmonary disease (COPD), and ‘asthma-COPD overlap.’ 2. Review newly approved and emerging treatment options for asthma and COPD. 3. Formulate a plan for implementing current guideline-recommended immunizations into comprehensive pulmonary care. 4. Evaluate the benefit of weight loss treatment in obese patients with obstructive sleep apnea. 5. Design an individualized treatment plan for a patient with comorbid pulmonary conditions. Speaker: Jessica L. Wallace, Pharm.D., BCPS Associate Professor, Department of Pharmacy and Pharmaceutical Sciences Lipscomb University College of Pharmacy Clinical Pharmacy Specialist Veterans Affairs Tennessee Valley Healthcare System Vanderbilt University Medical Center Nashville, TN   View Biography